Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients

• Published in: Genome medicine 2017-02, Vol.9 (1), p.21-21, Article 21
• Main Authors: Galloway-Peña, Jessica R, Smith, Daniel P, Sahasrabhojane, Pranoti, Wadsworth, W Duncan, Fellman, Bryan M, Ajami, Nadim J, Shpall, Elizabeth J, Daver, Naval, Guindani, Michele, Petrosino, Joseph F, Kontoyiannis, Dimitrios P, Shelburne, Samuel A
• Format: Article
• Language: English
• Subjects: Aged; Anti-Bacterial Agents - pharmacology; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Bacteria - genetics; Bacteria - isolation & purification; Bacteria - metabolism; Feces - microbiology; Female; Gastrointestinal Microbiome - drug effects; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - microbiology; Male; Middle Aged; RNA, Ribosomal, 16S; Saliva - microbiology; Sequence Analysis, DNA
• ISSN: 1756-994X; 1756-994X
• DOI: 10.1186/s13073-017-0409-1

Understanding longitudinal variability of the microbiome in ill patients is critical to moving microbiome-based measurements and therapeutics into clinical practice. However, the vast majority of data regarding microbiome stability are derived from healthy subjects. Herein, we sought to determine intra-patient temporal microbiota variability, the factors driving such variability, and its clinical impact in an extensive longitudinal cohort of hospitalized cancer patients during chemotherapy. The stool (n = 365) and oral (n = 483) samples of 59 patients with acute myeloid leukemia (AML) undergoing induction chemotherapy (IC) were sampled from initiation of chemotherapy until neutrophil recovery. Microbiome characterization was performed via analysis of 16S rRNA gene sequencing. Temporal variability was determined using coefficients of variation (CV) of the Shannon diversity index (SDI) and unweighted and weighted UniFrac distances per patient, per site. Measurements of intra-patient temporal variability and patient stability categories were analyzed for their correlations with genera abundances. Groups of patients were analyzed to determine if patients with adverse outcomes had significantly different levels of microbiome temporal variability. Potential clinical drivers of microbiome temporal instability were determined using multivariable regression analyses. Our cohort evidenced a high degree of intra-patient temporal instability of stool and oral microbial diversity based on SDI CV. We identified statistically significant differences in the relative abundance of multiple taxa amongst individuals with different levels of microbiota temporal stability. Increased intra-patient temporal variability of the oral SDI was correlated with increased risk of infection during IC (P = 0.02), and higher stool SDI CVs were correlated with increased risk of infection 90 days post-IC (P = 0.04). Total days on antibiotics was significantly associated with increased temporal variability of both oral microbial diversity (P = 0.03) and community structure (P = 0.002). These data quantify the longitudinal variability of the oral and gut microbiota in AML patients, show that increased variability was correlated with adverse clinical outcomes, and offer the possibility of using stabilizing taxa as a method of focused microbiome repletion. Furthermore, these results support the importance of longitudinal microbiome sampling and analyses, rather than one time measurements, in rese